- Lobbying
- horizon AND therapeutics
Lobbying Arrangements Results for 'Horizon Therapeutics'
Former Covered Federal Workers:
Other Lobbyists:
Issue | Client | Firm | Lobbyists | Start Date | Latest Filing Date |
---|---|---|---|---|---|
Details Issues related to orphan drugs and the value of innovative medicines. Legislation supporting the Orphan Drug Act. Issues regarding drug pricing. Issues pertaining to Medicare Part B and Part D.... |
Horizon Therapeutics USA, Inc.
|
Thorn Run Partners | |||
Details Line Extension Issues. |
Horizon Therapeutics (formally known as Horizon Pharma)
|
Gray Global Advisors, LLC | |||
Details Issues related to orphan drugs and the value of innovative medicines. |
Horizon Pharma USA, Inc.
Biopharmaceutical Development |
W Strategies, LLC | |||
Details Issues related to drug pricing and access, Medicare and Medicaid reimbursement Issues related to pharmaceutical industry, generally; Issues related to drug pricing and access, and Medicare and Medi... |
Horizon Therapeutics USA, Inc.
|
RICCHETTI INCORPORATED | |||
Details -H.R.7667, S.4348, reauthorization of FDA user fees -Implementation of the Orphan Drug Act of 1983 (P.L. 97-414) and orphan drug development -Implementation of the FDA Reauthorization Act (P.L. 11... |
Horizon Therapeutics USA (formerly Horizon Pharma)
|
FOLEY HOAG LLP | |||
Details Drug pricing; value-based arrangements. |
BioMarin
|
Horizon Government Affairs | |||
Details Issues pertaining to drug pricing and reimbursement, transparency and patient access. S 652 / HR 2620 "Safe Step Act," all provisions. Issues pertaining to the implementation of PL 97-414 "Orphan... |
Horizon Therapeutics USA, Inc. (FKA Horizon Pharma USA, Inc.)
|
in-house lobbying | |||
Details Policies and regulations impacting drugs for rare diseases and conditions; pharmaceutical pricing issues; 340B; Safe Step Act - HR 2630/S 652; FTC regulation of biopharma mergers and acquisitions P... |
HORIZON THERAPEUTICS USA, INC. (FKA HORIZON PHARMA USA, INC.)
|
JEFFREY J. KIMBELL & ASSOCIATES, INC. | |||
Details Implementation of provisions included in Subtitle B of PL. 117-169 - Inflation Reduction Act of 2022 Policies to remove barriers to physician prescribing decisions including in H.R. 2630/S.652 - Sa... |
Horizon Therapeutics USA, Inc. (formerly known as Horizon Pharma USA, Inc.)
|
THE MCMANUS GROUP | |||
Details H.R. 3 Lower Drug Costs Now; S. 102 Prescriptions Drug Price Relief Act of 2019; issues related to Safe step Act |
Amgen, Inc. FKA Horizon Therapeutics USA, Inc.
|
S-3 Group | |||
Details newborn screening, health equity and prescription drug affordability, FDA foreign inspection obligations |
Amicus Therapeutics, Inc.
|
Horizon Government Affairs | |||
Details Medicaid Value Based Purchasing |
Horizon Therapeutics (f/k/a) Horizon Pharma USA, Inc.
|
Sonoran Policy Group, LLC d/b/a Stryk Global Diplomacy, formerly known as Sonoran Policy Group, LLC | |||
Details Drug pricing policies, including The Safe Step Act. |
Horizon Therapeutics USA, Inc. (formerly Horizon Pharma USA, Inc.)
|
COVINGTON & BURLING LLP | |||
Details Lobbying related to business tax reform. |
Horizon Therapeutics USA, Inc.( previously known as Horizon Pharma USA, Inc.)
|
FGS Global (US) LLC (FKA FGH Holdings LLC) | |||
Details Utilization management. Prior-authorization in step therapy. |
Horizon Therapeutics USA, Inc.
|
Todd Strategy Group | |||
Details Issues related to pharmaceutical drugs; Issues related to drug pricing; Issues related to drug pricing in the Inflation Reduction Act of 2022 (PL 117-169); Issues related to Medicare Part D; Issues... |
Horizon Therapeutics
|
Forbes-Tate | |||
Details Affordability; Telehealth, Mental Health; Maternal Health; Fair Hospital Billing; Site Neutrality/Site neutral payment reform; Prior Authorization; Health Equity; Affordable Care Act; Transparency ... |
HORIZON BLUE CROSS BLUE SHIELD OF NEW JERSEY
|
in-house lobbying |